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served as controls. We focused on whether naloxone, ouabain, and bupivacaine, all agents
with reported anti-inﬂammatory effects on astrocytes, could affect the release of TNF-α and
IL-1β in microglia. Our results show that neither ultralow (1012 M) nor high (106 M)
concentrations of these agents had demonstrable effects on cytokine release in microglia.
The results indicate that anti-inﬂammatory substances exert speciﬁc inﬂuences on different
glial cell types. Astrocytes seem to be functional targets for anti-inﬂammatory substances
while microglia respond directly to inﬂammatory stimuli and are thus more sensitive to anti-
inﬂammatory substances like corticoids. The physiological relevance might be that astrocyte
dysfunction inﬂuences neuronal signalling both due to direct disturbance of astrocyte
functions and in the communication within the astrocyte networks. When the signalling
between astrocytes is working, then microglia produce less pro-inﬂammatory cytokines.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.Elsevier B.V.
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Microglia are considered as immunocompetent cells of the
CNS and are activated during pathological events such as
stroke, ischaemia, or brain trauma to cause a neuroinﬂam-
mation (Kreutzberg, 1996). In the normal brain, microgliaappear as highly branched or ramiﬁed cells and thought to
be quiescent. Activation of microglia alters their ramiﬁed
morphology to amoeboid and proliferative with migratory
behaviour. Surface molecules are expressed, cytokines are
released, and growth factor synthesis show an up-regulated
immunophenotype (Kettenmann et al., 2011).
b r a i n r e s e a r c h 1 5 3 9 ( 2 0 1 3 ) 3 4 – 4 0 35Activated microglia are known to release pro-
inﬂammatory cytokines, particularly tumour necrosis
factor-α (TNF-α) and interleukin-1β (IL-1β), and also nerve
growth factors, nitric oxide and prostanoids (Chao et al.,
1992). These substances are present during inﬂammatory
reactions and they produce long-term pain or hyperalge-
sia. Antagonism or neutralization of these factors can
reduce the pain (Marchand et al., 2005).
Several substances have been shown to exert anti-
inﬂammatory properties especially in astrocytes at extre-
mely low concentrations: naloxone, ouabain, and bupiva-
caine (Lundborg et al., 2010, 2011; Block et al., 2012).
Extremely low doses, at picomolar concentrations, of
opioid receptor antagonists, such as naloxone or naltrex-
one, have been shown to enhance the efﬁcacy and speci-
ﬁcity of morphine and related opioid analgesics in mice
and postoperative patients (Crain and Shen, 2000). Extre-
mely low doses of naltrexone inhibit the development of
spinal morphine antinociceptive tolerance, and clinical
studies demonstrated that this may be due to attenuated
glial activation (Mattioli et al., 2010). Ouabain, a digitalis-
derived glycoside is a well-recognized Naþ/Kþ-ATPase inhibitor,
especially pronounced at high concentrations. It alsoFig. 1 – (A) Microglial cultures were stained with antibodies agai
cells are microglia expressing TLR4 receptors. The two antibodie
Western blot. Cultures were incubated with 1 ng/ml LPS for 0.5,
density. (C) TLR4 is also shown as a band at 70 kDa, reﬂecting
signiﬁcance was analysed using one way ANOVA followed by D
were found.enhances LPS down-regulated iNOS activity in peritoneal
macrophages (Sowa and Przewlocki, 1997). Ouabain, at extre-
mely low concentrations, nanomolar and picomolar, stimu-
lates Naþ/Kþ-ATPase activity (Zhang et al., 2008), and
activates complex signalling cascades in kidney cells
(Holthouser et al., 2010), and in cardiac and smooth muscle
cells (Manunta et al., 2010). Ouabain also decreases the
release of IL-1β in astrocytes (Forshammar et al., 2011).
Bupivacaine is known to block Naþ channels at high concen-
trations and change the excitability of action potentials.
Clinically, this drug has been used in the treatment of various
inﬂammation-related conditions and diseases (Cassuto et al.,
2006), and to treat long-term pain in both cancer and non-
cancer patients (Deer et al., 2002). Later it has been observed
that local anaesthetics possess anti-inﬂammatory properties
through their effects on cells of the immune system. These
agents also attenuate the release of the pro-inﬂammatory
cytokines TNF-α and IL-1β from intestinal cells (Lahav et al.,
2002; Bedirli et al., 2011).
The purpose with the present study was to investigate if a
number of non-steroid anti-inﬂammatory substances, admi-
nistered within a wide dose range (1012 M to 106 M)
inﬂuence microglial release of pro-inﬂammatory cytokines.nst OX42, or with antibodies against TLR4, revealing that the
s are then merged. (B) Microglia express TLR4 visualised with
1, 4, 8, or 24 h. The TLR4 expression is shown as integrated
the time exposure to LPS. Statistical analysis: The level of
unnett's multiple comparisons test. No signiﬁcances
Fig. 2 – Microglia incubated with 1 ng/ml LPS for 0.5, 1, 4, 8,
or 24 h. (A) TNF-α release with accumulating amount over
time. After 4 h incubation a small release of TNF-α was
observed, but it was signiﬁcant ﬁrst after 8 h (n¼8), and
increased after 24 h incubation (n¼8). (B) IL-1β release was
small after 1, 4, and 8 h, and was signiﬁcant after 24 h (n¼6).
Statistical analysis: The level of signiﬁcance was analysed
using one way ANOVA followed by Dunnett's multiple
comparisons test. Data are mean7SEM. nn¼Po0.01,
nnn¼Po0.001.
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2.1. Characterisation
The microglial cells were stained with antibodies against the
microglial speciﬁc antigen OX42, and with antibodies against
TLR4, revealing that these cells do express TLR4 receptors
(Fig. 1(A)).
Microglia express TLR4 visualised withWestern blot (Fig. 1(B)).
Cultures were incubated with LPS for 0.5, 1, 4, 8, or 24 h. TLR4 is
seen as a band at approximately 70 kDa. Full length TLR4 is
observed at approximately 90 kDa, but cleavage fragments have
been observed at 30 and 60 kDa (Zager et al., 2007). Since no other
bands were present on the membrane the TLR4 antibody was
considered speciﬁc even though it did not match the full size
TLR4. The TLR4 is measured as integrated density and presented
as % of 0 h (Fig. 1(C)).
2.2. Cytokine release after LPS incubation
Microglia incubated with LPS for 0.5, 1, 4, 8, or 24 h released
TNF-α and IL-1β in accumulating amount over time. After 4 h
incubation a small release of TNF-α was observed, but it was
not signiﬁcant until 8 h of incubation (Po0.01; n¼8), with
increasing release after 24 h incubation (P40.001; n¼8) (Fig. 2(A)).
IL-1β release was small after 1, 4, and 8 h, and was signiﬁcantly
accumulated after 24 h (Fig. 2(B)).
Microglia were treated with dexamethasone or corticoster-
one 30min before the cells were incubated with a cocktail of
LPS and dexamethasone or corticosterone. TNF-α release was
attenuated after both dexamethasone and corticosterone treat-
ment (Po0.001; n¼9) (Fig. 3(A)). IL-1β release was attenuated
after both dexamethasone and corticosterone treatment
(Po0.001; n¼9) (Fig. 3(B)). Dexamethasone and corticosterone
were used as control substances to evaluate that the system
was validated to test anti-inﬂammatory substances.
Microglia were treated with ultralow (1012 M) or high
(106 M) concentrations of naloxone, ouabain, or bupivacaine,
30 min before the cells were incubated with a cocktail of LPS
and naloxone, ouabain, or bupivacaine for 24 h, respectively.
Naloxone, ouabain, or bupivacaine were not able to attenuate
the TNF-α release after LPS incubation (n¼9). Instead nalox-
one and ouabain at ultralow concentration increased the
TNF-α release (Fig. 3(A)). None of the different substances
were able to decrease the IL-1β release (n¼9) (Fig. 3(B)).
The selection of choosing one ultralow and one high con-
centration of the anti-inﬂammatory substances are due to
results obtained from concentration curves, and results
obtained from astrocytes. LPS-induced TNF-α release from
microglia after stimulation with bupivacaine, 1018–103 M,
shows that bupivacaine was not able to decrease the TNF-α
release after LPS incubation, except at 103 M, where the cells
died (Fig. 4). The other concentration curves for naloxone and
ouabain showed similar results, (not shown). LPS-induced IL-1β
release from astrocytes after naloxone and ouabain stimulation
with different concentrations has earlier been published by our
group (Forshammar et al., 2011), as well as with bupivacaine
stimulation (Block et al., in press). The TNF-α release is very
small in our astrocytes (Andersson et al., 2005).3. Discussion
After nerve injury a course of events takes place where the
microglial receptor TLR4 has been implicated (Tanga et al.,
2005). Signals from the surrounding milieu trigger microglial
activation through this receptor, where after the cells will be
activated and release pro-inﬂammatory cytokines. Activation
of TLR4 by the inﬂammatory stimulus LPS (Neher et al., 2011)
results in increased expression of TNF-α in microglia (Zhou
et al., 2010). In our microglial cell model we see increases of
both TNF-α and IL-1β after 8 h and 24 h, respectively of LPS
incubation. The cells express TLR4, even at a high level before
they were stimulated with LPS, which can be due to a high
TLR4 protein content already at time point zero. TNF-α is
released in response to inﬂammation or other types of insult
where it can act protective to neurons (Fontaine et al., 2002),
and astrocytes (Kuno et al., 2006) because it is able to
Fig. 3 – Cells were treated with dexamethasone, (Dex, 106 M),
corticosterone (Cort, 106 M), naloxone (Nalox, 1012,106),
ouabain (Ouab, 1012, 106), or bupivacaine (Bup, 1012, 106)
30min before incubation with LPS (1 ng/ml) and the
substances, respectively. Data are % of responses to LPS alone
(LPS in ﬁgure). (A) TNF-α release. (B) IL-1β release. (n¼9).
Statistical analysis: The level of signiﬁcance was analysed
using one way ANOVA followed by Dunnett's multiple
comparisons test. Data are mean7SEM. nnn¼Po0.001,
nn¼Po0.01 (both vs. LPS alone). n.s¼non signiﬁcant.
Fig. 4 – Microglia treated with bupivacaine, (Bup, 1018–
103 M) 30 min before incubation with LPS (1 ng/ml) and Bup
for 24 h. Control is without LPS stimulation. Bup was not
able to decrease the TNF-α release after LPS incubation,
except at 103 M, where the cells died. TNF-α release is
expressed as ng TNF-α/mg protein.
b r a i n r e s e a r c h 1 5 3 9 ( 2 0 1 3 ) 3 4 – 4 0 37encourage the expression of anti-apoptopic and anti-oxidative
proteins and peptides. It has also been demonstrated that
microglia protect neurons against ischaemia through the synth-
esis of TNF-α (Lambertsen et al., 2009).As we demonstrate, inﬂammatory activated microglial cells
are stimulated by signals, which activate TLR4 and the cells
change their release of pro-inﬂammatory cytokines. One tenta-
tive target to restore these processes would be to inhibit the
inﬂammation activating cellular changes and to decrease the
pro-inﬂammatory cytokine release. Astrocytes and microglia
are known to play a role in the development, spread, and
potentiation of neuroinﬂammation (DeLeo et al., 2004; Milligan
and Watkins, 2009), and we have recently shown that Ca2þ
signalling in astrocytes is disturbed when inﬂuenced by inﬂam-
matory stimuli (Hansson, 2010). Two substances with proposed
anti-inﬂammatory properties at extremely low concentrations,
naloxone and ouabain, demonstrate an ability to limit the
inﬂammatory induced alterations in astrocytes (Forshammar
et al., 2011). We conclude that this is a note-worthy step in
understanding astrocyte responses and neuroinﬂammatory
mechanisms. There are more substances that have been
proposed to have anti-inﬂammatory qualities and up-regulate
or restore parameters related to inﬂammation especially at
extremely low concentrations in astrocytes. In the present
study we wanted to examine a number of substances, which
have anti-inﬂammatory effects on astrocytes, and we wanted
to test them in LPS-activated microglia. The substances tested
were naloxone, ouabain, and bupivacaine. We also used some
well-known classical anti-inﬂammatory substances, dexa-
methasone and corticosterone, as control substances. They
attenuated both TNF-α and IL-1β releases. Glucocorticoids pre-
vent swelling of cells and release of pro-inﬂammatory cytokines
(Chao et al., 1992; Lekander et al., 2009), and decrease the
number of activated microglia (Hinkerohe et al., 2010). These
two glucocorticoids are frequently used in acute pain states
(De Oliveira et al., 2011). On the other hand, glucocorticoids can
also cause extracellular accumulation of glutamate, which could
cause excitotoxicity and acute stress (Jacobsson et al., 2006).
Naloxone at ultralow concentration, prevented LPS induced
down-regulation of Naþ/Kþ-ATPase (Forshammar et al., 2011),
and down-regulated LPS-induced endomorphin stimulated Ca2þ
transients in astrocytes (Block et al., 2012), as well as reversed
down-regulation of the Naþ dependent glutamate transporter
(Tsai et al., 2009). So far naloxone has not been able to decrease
the release of pro-inﬂammatory cytokines in LPS-activated
astrocytes or microglia. Instead a small increase of TNF-α was
observed in microglia.
Ouabain also enhances LPS down-regulated iNOS activity
in peritoneal macrophages (Sowa and Przewlocki, 1997).
It decreased the IL-1β release in astrocytes (Forshammar et al.,
2011), but showed a small increase of TNF-α in microglia.
It can be speculated in if the increased release of TNF-α with
ultralow concentrations of naloxone or ouabain might have a
protective effect. Exogenous TNF-α as well as TNF-α produced
by astrocytes, induces production of neurotrophic factors
such as nerve growth factor (NGF) and glial cell line-derived
neurotrophic factor GDNF by astrocytes (Kuno et al., 2006).
TNF-α as well as IL-1β are considered to initiate a cascade of
activation of cytokines and growth factors. Recent reports
indicate that TNF-α can have dual actions mediated via
different receptors, which can be responsible for neurotoxic
and neuroprotective effects, respectively (Mika, 2008). Inter-
estingly it was observed that both IL-1 receptor antagonists
and intrathecal administration of IL-1α prevent neuronal
b r a i n r e s e a r c h 1 5 3 9 ( 2 0 1 3 ) 3 4 – 4 038apoptosis, while such actions were not seen after IL-1β
administration (Mika, 2008). Both IL-1α and IL-1β act on the
IL-1 receptor. The mechanisms behind IL-1β and its receptor
are still unclear regarding responses to inﬂammation and
provision of any form of protection.
Another substance of interest is the local anaesthetic
bupivacaine, which can block neural activity and prevent
nerve-injury-induced spinal microglia activation (Wen et al.,
2011). In our microglial cultures, pre-stimulation with bupi-
vacaine prior to cell activation by LPS did not suppress the
TNF-α or IL-1β releases. However, bupivacaine decreases the
IL-1β release at ultralow concentration in astrocyte primary
cultures (Block et al., in press).
As none of the tested substances, which have been shown
to have anti-inﬂammatory effects on astrocytes in extremely
low concentrations, decreased the cytokine release, we
extended the study to include also treatment of microglial
with high concentrations of these substances. Naloxone and
ouabain both attenuated the increased TNF-α release at high
concentration, but showed no ability to decrease the cytokine
release compared with controls.4. Experimental Procedures
4.1. Chemicals
All chemicals were obtained from Sigma-Aldrich (St Louis,
MO, USA) if not stated otherwise.
The experimental protocols were approved by the
Ethical Committee in Gothenburg for Laboratory Animals
(Nos. 205-2010).
4.2. Microglial cultures
Puriﬁed microglial cells were obtained from astroglial-enriched
cultures, rat cerebral cortex, grown as previously described by
Hansson et al. (1984). Conﬂuent astroglial-enriched cultures,
no more than 6 weeks old, were shaken for 30min at 37 1C
and 240 rpm on an orbital shaker in an incubator with a
humidiﬁed atmosphere of 95% air and 5% CO2. Culture medium,
minimum essential medium (MEM), with suspended microglial
cells was collected. The microglial cell suspension was plated
in six well plates (NUNC), both with or without glass coverslips,
and cells were allowed to adhere for 30min in the incubator.
Together with nonadherent cells, the culture medium was
removed from the wells and discarded. Additional medium
containing microglia was added. This was repeated until a
satisfactory amount (50 μg total protein per well) of microglia
was obtained in each well. The culture medium was then
replaced with fresh, pre-warmed (37 1C) supplemented MEM,
and microglial cells were kept in the incubator and allowed to
rest overnight (Persson et al., 2006).
4.3. Cell treatments
Cells were incubated with lipopolysaccharide (LPS, Escher-
ichia coli O111:B4) (1 ng/ml) for 0.5, 1, 4, 8, or 24 h. Some cells
were treated with dexamethasone or corticosterone (106 M)
for 30 min before they were incubated with LPS in a cocktailin un-supplemented MEM. Other cells were incubated with
LPS and treated with naloxone (1012, 106 M), ouabain (1012,
106 M), or the local anaesthetics bupivacaine (1012, 106 M) in
the same way as above.
4.4. Immunocytochemistry
The cells were ﬁxed with 4% paraformaldehyde (Histolab Pro-
ducts AB, Gothenburg, Sweden) for 10min and washed twice
with phosphate buffer saline (PBS) (Invitrogen) containing 1%
BSA (PBS–BSA). The cells were permeabilised with PBS–BSA
containing 0.05% saponine (PBS–BSA–Sap) for 20min. Thereafter
the cells were incubated for 1 h with a cocktail of rabbit
polyclonal antibody against Toll-like receptor, TLR4, (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted 1:100 and a mono-
clonal antibody against OX42 diluted 1:100 in PBS–BSA–Sap.
The cells were washed with PBS–BSA–Sap. for 35min and
then incubated with a mixture of FITC conjugated F(ab′)2
donkey anti-rabbit IgG and Texas Red conjugated F(ab′)2 donkey
anti-mouse IgG secondary antibodies (Jackson Immuno
Research, Westgrove, USA), both diluted in PBS–BSA–Sap. The
cells were washed with PBS–BSA–Sap for 35min and ﬁnally
rinsed with PBS. Controls were treated similarly except for
incubations with the primary antibodies. The cover slips were
mounted on microscope slides with a ﬂuorescent mounting
medium (DAKO, Glostrup, Denmark) and viewed in a Nikon
Eclipse 80i microscope. Pictures were taken with a Hamamatsu
C5810 colour intensiﬁed 3CCD camera.
4.5. SDS-PAGE and western blotting
Cells were rinsed twice in phosphate buffered saline (PBS)
and immediately lysed 20 min on ice in cold RIPA lysis buffer.
The procedure was done according to the process described
by Persson et al. (2005). Separate aliquots were taken for
protein concentration determination. All samples were cor-
related for total protein contents and an equal loading of
20 mg total protein of each sample was applied in each lane of
the gel. SDS-PAGE were conducted using the Novex pre-cast
gel system (Invitrogen) according to the manufacturer's
recommendations using 4–12% Bis-–Tris gels (Invitrogen) at
200 V for 50 min. The separated proteins were then trans-
ferred at 30 V for 60 min to a nitrocellulose membrane
(Invitrogen) using NuPAGE transfer buffer (Invitrogen) sup-
plemented with methanol and NuPage antioxidant. The
membranes were rinsed twice with distilled water and the
proteins were visualised with Ponceau S solution (Sigma).
Proteins were blocked with 5% fat free skim milk (Semper AB,
Sundbyberg, Sweden) in TBST (50 mM Tris–HCl, 150 mM NaCl
and 0.05% Tween) for 60 min at room temperature. The
membranes were then probed with primary antibodies over-
night (þ4 1C), washed 42 min with TBST, and subsequently
probed with secondary horse-radish peroxidase (HRP) con-
jugated secondary antibodies for 60 min at room tempera-
ture, and ﬁnally washed several times in TBST. The primary
antibody used was rabbit polyclonal TLR4 diluted 1:500. The
secondary antibody used were HRP-conjugated donkey anti
rabbit F(ab′)2 fragment (both from Jackson Immunoresearch)
diluted 1:10000. Both primary and secondary antibodies were
diluted in 5% fat free skim milk in TBST. Protein was then
b r a i n r e s e a r c h 1 5 3 9 ( 2 0 1 3 ) 3 4 – 4 0 39detected with an enhanced chemiluminescence kit (PerkinEl-
mer Inc., Waltham, MA, USA) and visualised with a FUJI Film
LAS-3000 (Tokyo, Japan).4.6. Cytokine release
Enzyme-linked immunoabsorbent assay (ELISA) was performed
with respect to TNF-α using OptEIA kits (BD Biosciences, San
Jose, CA) and IL-1β using Nordic Biosite, Täby, Sweden.
Supernatants from puriﬁed microglial cell cultures were
collected after microglia had been stimulated for 0.5–24 h. ELISA
was performed on the supernatants according to the manufac-
turer's instructions. All stimulations were performed in a total
volume of 1ml MEM. Cell lysates were produced by harvesting
remaining cells with a cell scraper in 1 M NaOH, and aliquots
were taken for protein determination. ELISA plates were ana-
lysed at 450 nm with a Molecular Devices VersaMax microplate
reader and were analysed using SoftMax Pro 4.8, both from
Molecular Devices (Sunnyvale, CA, USA).4.7. Protein determination
The protein determination assay was performed in accor-
dance with the manufacturer's instructions using a DC
Protein Assay (Bio-Rad, Hercules, CA, USA), based with some
modiﬁcations on the method used by Lowry et al. (1951).
Both standard (0–4 mg/ml BSA) and samples were mixed with
the reagents, incubated for 15 min at room temperature, read
at 750 nm with a Versa-max microplate reader, and analysed
using SoftMax Pro 4.8.4.8. Statistics
Differences between groupedmean values were identiﬁed using
one way ANOVA followed by Dunnett's multiple comparisons
test. Error bars show standard error of the mean (SEM).5. Conclusion
In a microglial cell culture we observed that exposure of LPS was
associated with a release of both TNF-α and IL-1β, which
increased over time. Dexamethasone and corticosterone attenu-
ated these responses. Other investigated anti-inﬂammatory
agents in this study, which previously have been shown to
counter a LPS-dependent release of TNF-α and IL-1β in astro-
cytes, were not associated with corresponding effects in micro-
glial cells. After inﬂammation, increases of pro-inﬂammatory
cytokines are observed. Astrocytes seem to be better target cells
for anti-inﬂammatory substances than microglia. The physiolo-
gical relevance might be that communication within the astro-
cyte networks seems to be of importance. If the signalling
between astrocytes is working, thereby the microglia show a
normal and non-inﬂammatory state. Thus, our ﬁndings indicate
that anti-inﬂammatory substances have a cell-type speciﬁc
capacity to modulate pro-inﬂammatory reactions in glial tissues.Acknowledgments
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